Keyphrases
Myeloma
100%
Therapeutic Effect
100%
Histone Deacetylase Inhibitor (HDACi)
100%
Subtype Selectivity
100%
Bone Disease
100%
Novel Subtype
100%
Chidamide
100%
Cytotoxicity
25%
Multiple Myeloma
25%
Bone Loss
25%
Cell-to-cell
12%
Tumor Burden
12%
JNK1
12%
Tumor-associated
12%
New Subtype
12%
Hematological Malignancies
12%
Therapeutic Target
12%
Murine Model
12%
Protective Effect
12%
Clinical Application
12%
C-Fos
12%
Cell Apoptosis
12%
AKT1
12%
Cell Cycle Arrest
12%
Human Mesenchymal Stem Cells (hMSCs)
12%
Family Protein
12%
P21 Protein
12%
China
12%
Myeloma Cells
12%
Osteoclast
12%
Nuclear Factor
12%
Histone Deacetylases
12%
Osteoclast Differentiation
12%
Cathepsin K
12%
NFATc1
12%
P-p38
12%
Nontumor
12%
Bone Protection
12%
Tumor-bearing Mice Model
12%
Caspase Family
12%
Osteoclast Resorption
12%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloma
100%
Therapeutic Effect
100%
Histone Deacetylase Inhibitor
100%
Bone Disease
100%
Tucidinostat
100%
Neoplasm
37%
Cytotoxicity
25%
Multiple Myeloma
25%
Mouse Model
12%
Receptor
12%
Hematologic Malignancy
12%
Osteoclast Differentiation Factor
12%
Caspase
12%
Protein Kinase B
12%
Nuclear Factor
12%
Protein P21
12%
Histone Deacetylase
12%
Protein P27
12%
Cathepsin K
12%